What is the WBIO.CN share price today?

This page shows the latest available WPD Pharmaceuticals Inc. (WBIO.CN) price with its change against the prior close. Values are delayed or previous-close, not real-time.

Where is WPD Pharmaceuticals Inc. listed?

WPD Pharmaceuticals Inc. trades on the Canadian Securities Exchange under the symbol WBIO.CN, ISIN CA92941F2044.

How large is WPD Pharmaceuticals Inc.?

Its market capitalisation is approximately 324.76K CAD, based on the latest available price and share count from our data provider.

Canadian Securities Exchange (CSE) · WBIO.CN · ISIN CA92941F2044

WPD Pharmaceuticals Inc.

No trading activity has been reported for this listing since February 20, 2025. It may be delisted, halted or inactive.

0.0700 CAD

February 20, 2025

WPD Pharmaceuticals Inc. (WBIO.CN) trades on the Canadian Securities Exchange and operates in the Biotechnology industry. Its market capitalisation is approximately 324.76K CAD. The company reports around 16 employees. Its ISIN is CA92941F2044. This page shows the latest available price, the day and 52-week ranges and an interactive chart. Quotes are delayed and are not intended for order execution.

Key facts

Exchange

Canadian Securities Exchange (CSE)

ISIN

CA92941F2044

Sector

Healthcare

Industry

Biotechnology

Country

Market cap

324.76K CAD

Employees

Previous close

0.19 CAD

Day range

0.07 – 0.07

52-week range

0.07 – 1.13

Volume

50-day average

0.18 CAD

200-day average

0.23 CAD

Asset type

Equity

About WPD Pharmaceuticals Inc.

WPD Pharmaceuticals Inc., a biopharmaceutical company based in Vancouver, Canada, specializes in the research and advancement of therapeutic products for oncology and infectious diseases. The company's diverse drug development pipeline features multiple promising candidates: WPD101 and WPD103 are both in pre-clinical stages, targeting brain cancers, including glioblastoma and glioblastoma multiforme respectively. Also in pre-clinical development is WPD102, aimed at Uveal Melanoma. In more advanced clinical stages, Berubicin is undergoing Phase 1 trials for glioblastoma, while WP1066, also in Phase 1 clinical trials, is being investigated for central nervous system tumors, pancreatic cancer, and ocular tumors. Additionally, the pipeline includes WP1732 for pancreatic cancer and WP1220 for cutaneous T-cell lymphoma. Annamycin is currently in Phase I/II clinical trials for acute myeloid leukemia (AML) and is also being explored for lung metastasis.

Company website

Frequently asked

What is the WBIO.CN share price today?: This page shows the latest available WPD Pharmaceuticals Inc. (WBIO.CN) price with its change against the prior close. Values are delayed or previous-close, not real-time.
Where is WPD Pharmaceuticals Inc. listed?: WPD Pharmaceuticals Inc. trades on the Canadian Securities Exchange under the symbol WBIO.CN, ISIN CA92941F2044.
How large is WPD Pharmaceuticals Inc.?: Its market capitalisation is approximately 324.76K CAD, based on the latest available price and share count from our data provider.

All WPD Pharmaceuticals Inc. data comes from exchange and provider feeds for the Canadian Securities Exchange and is published for information, not as investment advice.

Real-time quotes are not licensed; prices are delayed or previous close, so they may lag the market by 15 minutes or a full session. Information only, not for trading. Where a figure is not covered by our licensed sources, the page says so rather than showing a substitute.